Minocycline
- Generic Name
- Minocycline
- Brand Names
- Amzeeq, Arestin, Dynacin, Minocin, Minolira, Solodyn, Ximino, Zilxi
- Drug Type
- Small Molecule
- Chemical Formula
- C23H27N3O7
- CAS Number
- 10118-90-8
- Unique Ingredient Identifier
- FYY3R43WGO
- Background
Minocycline was first described in the literacture in 1966. It is a second generation tetracycline antibiotic that is active against gram-negative and gram-positive bacteria. Like other semisynthetic tetracyclines, minocycline has modifications to carbons 7-9 on the D ring to generate higher efficacy than previous tetracyclines.
Minocycline was granted FDA approval on 30 June 1971.
- Indication
Oral and topical minocycline are indicated to treat inflammatory lesions of acne vulgaris. Subgingival microspheres are indicated as an adjunct treatment in the reduction of pocket depth in adults with periodontitis. Oral and intravenous formulations are indicated to treat infections of susceptible microorganisms. These include rickettsiae, Mycoplasma pneumoniae, Chlamydia trachomatis, Chlamydophila psittaci, Chlamydia trachomatis, Ureaplasma urealyticum, Borrelia recurrentis, Haemophilus ducreyi, Yersinia pestis, Francisella tularensis, Vibrio cholerae, Campylobacter fetus, Brucella species, Bartonella bacilliformis, Klebsiella granulomatis, Escherichia coli, Enterobacter aerogenes, Shigella species, Acinetobacter species, Haemophilus influenzae, and Kelbsiella species.
- Associated Conditions
- Bartonellosis, Brucellosis, Campylobacter fetus, Chancroid, Cholera (Disorder), Conjunctivitis, Inclusion, Granuloma Inguinale, Lymphogranuloma Venereum, Nongonococcal urethritis, Periodontitis, Plague, Psittacosis, Q Fever, Relapsing Fever, Respiratory Tract Infections (RTI), Rickettsia Infections, Rickettsialpox, Rocky Mountain Spotted Fever, Trachoma, Tularemia, Typhus infections, Inflammatory lesions
Minocycline Accelerates Intracerebral Hemorrhage Absorption
- Conditions
- Intracerebral Hemorrhage
- Interventions
- Other: starch
- First Posted Date
- 2022-11-29
- Last Posted Date
- 2022-11-29
- Lead Sponsor
- Second Affiliated Hospital, School of Medicine, Zhejiang University
- Target Recruit Count
- 90
- Registration Number
- NCT05630534
Minocycline in Neurocognitive Outcomes - Sickle Cell Disease
- Conditions
- Sickle Cell DiseaseCognitive DysfunctionCognitive ImpairmentCognitive DeclineCognitive ChangeCognitive DeficitNeuroinflammatory Response
- Interventions
- Drug: Placebo
- First Posted Date
- 2022-11-04
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- University of Cincinnati
- Target Recruit Count
- 30
- Registration Number
- NCT05605366
Impact of DFD-29 on Microbial Flora of Healthy, Adult Human Subjects When Administered Over 16 Weeks
- Conditions
- Rosacea
- Interventions
- Other: Placebo
- First Posted Date
- 2022-10-28
- Last Posted Date
- 2023-08-02
- Lead Sponsor
- Journey Medical Corporation
- Target Recruit Count
- 60
- Registration Number
- NCT05597462
- Locations
- 🇺🇸
3A Research, LLC, El Paso, Texas, United States
Efficacy of Colistin Monotherapy Versus Colistin Plus Minocycline for Carbapenem-Resistant A. Baumannii Infection
- Conditions
- Acinetobacter Infections
- Interventions
- First Posted Date
- 2022-10-19
- Last Posted Date
- 2023-01-18
- Lead Sponsor
- Mahidol University
- Target Recruit Count
- 94
- Registration Number
- NCT05586815
- Locations
- 🇹🇭
Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand
Efficacy of Combination Therapy With Minocycline for Treatment of Stenotrophomonas Maltophilia Infections
- Conditions
- Hospital Infections
- Interventions
- First Posted Date
- 2022-10-12
- Last Posted Date
- 2023-01-10
- Lead Sponsor
- Mahidol University
- Target Recruit Count
- 112
- Registration Number
- NCT05575427
- Locations
- 🇹🇭
Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand
Effects of AMP Application After Non-surgical Periodontal Therapy on Treatment of Periodontitis
- Conditions
- Periodontitis
- Interventions
- First Posted Date
- 2022-09-07
- Last Posted Date
- 2024-04-30
- Lead Sponsor
- Beijing Stomatological Hospital, Capital Medical University
- Target Recruit Count
- 51
- Registration Number
- NCT05530252
- Locations
- 🇨🇳
BeijingSHCMU, Beijing, China
Minocycline for Acute Ischemic Stroke Undergoing Endovascular Treatment Due to Basilar Artery Occlusion (MIST-B)
- Conditions
- Ischemic Stroke, AcuteMinocyclineEndovascular TreatmentBasilar Artery Occlusion
- Interventions
- First Posted Date
- 2022-08-23
- Last Posted Date
- 2022-12-16
- Lead Sponsor
- Xijing Hospital
- Target Recruit Count
- 90
- Registration Number
- NCT05512910
- Locations
- 🇨🇳
Department of Neurology, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China
Effects of Minocycline on Patients With Ischemic Stroke Undergoing Intravenous Thrombectomy
- First Posted Date
- 2022-08-04
- Last Posted Date
- 2024-07-23
- Lead Sponsor
- Xijing Hospital
- Target Recruit Count
- 180
- Registration Number
- NCT05487417
- Locations
- 🇨🇳
Xijing Hospital, Xi'an, China
Minocycline for Chronic Autoimmune Uveitis
- First Posted Date
- 2022-07-26
- Last Posted Date
- 2023-04-18
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 10
- Registration Number
- NCT05474729
- Locations
- 🇨🇳
Zhongshan Ophthalmic Center, Guangzhou, Guangdong, China
Minocycline Treatment for Cystoid Macular Edema
- First Posted Date
- 2022-07-26
- Last Posted Date
- 2023-04-19
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 5
- Registration Number
- NCT05474950
- Locations
- 🇨🇳
Zhongshan Ophthalmic Center, Guangzhou, Guangdong, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.